Digital neurotherapy is solving one of healthcare’s most persistent problems: what happens to patients after they leave the clinic. For people recovering from stroke, dementia, or traumatic brain injury, the drop-off in care intensity after hospital discharge is where recovery stalls. Vienna-based nyra health built a platform specifically to close that gap, and the startup has secured €20 million in Series A funding to scale it.
This is not a niche bet. Neurological diseases cost Germany alone €65 billion annually, largely because follow-up care is insufficient once patients go home. nyra health’s AI-powered platform, myReha, keeps therapy going after discharge. That’s the core of what this funding round is about.
The Real Problem:
Most rehabilitation systems are built around the hospital stay. Once a patient is discharged, therapy frequency drops sharply. For neurological conditions like stroke and aphasia, this is a serious clinical issue. The brain needs consistent, high-density training to rebuild pathways. Gaps in that training slow recovery and increase long-term costs for insurers and healthcare systems.
nyra health addresses this by creating a continuous therapy loop from inpatient care to long-term home use. The platform connects clinical teams and patients across the full recovery timeline, not just during the acute phase.
How myReha Works:
myReha is an MDR Class IIa-certified therapy app available on iOS and Android. It focuses on speech, cognition, fine motor skills, and everyday abilities. The AI layer is doing real work here: proprietary speech models analyze pronunciation, word retrieval, syntax, and semantic structure. The platform simultaneously tracks reaction times, error patterns, and training dynamics.
Based on that data, therapy content automatically adapts to a patient’s current performance, fatigue levels, and progress. Patients aren’t working through static exercise sheets. They get a training experience that shifts with them in real time.
For clinics and therapy practices, nyra insights provides a web-based management platform. Therapists can monitor language development, track therapy intensity, view progress curves, and auto-generate documentation. The AI-supported Content Studio generates personalized therapy materials dynamically, based on individual performance data.
Clinical Adoption and Insurance Coverage:
The numbers behind nyra health’s traction are worth noting. The platform is used in over 100 neurological clinics and is part of the standard care program run by Deutsche Rentenversicherung, Europe’s largest rehabilitation provider. Twenty-eight statutory and private health insurance companies in Germany, Austria, and Switzerland automatically reimburse myReha, giving over 40 million insured individuals direct access to structured home therapy.
The company also reports that patients using myReha show 93% stronger improvement in language and cognitive skills compared to standard therapy, based on a 12-week randomized controlled trial. Patient satisfaction in the German Pension Insurance aftercare program sits at 98%.
These are clinical and operational proof points that mattered to investors. Armira Growth led the Series A round, with Wellington Partners, Crane Venture Partners, and EVER Pharma all re-participating. Armira’s managing partner Christian Figge described nyra health as a “true category creator” for connecting the entire neurological care chain for the first time.
What the Funding Enables:
The €20 million will go toward three areas. First, deeper integration across the DACH region with additional clinic groups and expanded reimbursement models in Germany, Austria, and Switzerland. Second, a US market launch planned in collaboration with an international pharmaceutical partner. Third, continued AI development through a €4.2 million funded research project being run in collaboration with leading US research universities.
The US entry is a notable move. American healthcare has a similar structural problem with post-discharge neurological care, and the lack of universal reimbursement infrastructure there means nyra health will need to navigate a different market dynamic than it has in Germany. The partnership model with a pharmaceutical company is a sensible entry strategy for that environment.
The research component is also meaningful. Expanding multimodal AI models for therapeutic interaction and diagnostics, not just content delivery, signals that nyra health is building toward a more comprehensive clinical intelligence layer, not just a therapy app.
